Q/C Technologies Inc (NASDAQ: QCLS) is a pre-revenue technology company developing laser-based computing hardware for cryptocurrency mining, decentralized computing, and AI applications. Its intended revenue model centers on licensing, hardware sales, and leasing arrangements built around its qc-LPU100 laser processing unit, which remained in prototype development as of the 10-K filed April 15, 2026. The company began its strategic transition toward laser-based computing in September 2025, following a series of prior name and business changes, including operating as MyMD Pharmaceuticals and TNF Pharmaceuticals before rebranding to Q/C Technologies in September 2025. Early commercialization activity includes a licensing arrangement with LightSolver and plans for pilot deployments targeting DePin Token infrastructure and AI workloads. No material revenues had been generated from this business as of the fiscal year ended December 31, 2025. The company carries an accumulated deficit and has financed operations through equity and convertible preferred stock issuances. PharmaCyte Biotech Inc. beneficially owned more than 10% of outstanding common stock as of April 12, 2026.

Revenue model

Licensing revenue through a channel partner arrangement (LightSolver), with planned future revenues from hardware sales and leasing of qc-LPU100 systems. No material revenues confirmed as of fiscal year ended December 31, 2025.

Products and services

qc-LPU100: a laser processing unit in prototype development as of April 2026, targeting cryptocurrency mining, DePin Token infrastructure, decentralized computing, and AI workloads. Intellectual property position being expanded through the LightSolver licensing arrangement.

Customers and end markets

No disclosed paying customers as of the 10-K filed April 15, 2026. Target end markets include cryptocurrency mining operators, DePin Token network participants, decentralized computing platforms, and AI application developers.

Value-chain role

Hardware developer and licensor at the component and system level, distributing through a channel partner (LightSolver). Plans to expand into software and services alongside hardware to establish recurring revenue streams.

Geographic exposure

U.S.-incorporated (Delaware). International operations subject to U.S. export controls (ITAR, Export Administration Regulations), EU MiCA regulations, and other jurisdiction-specific import and export frameworks. No specific international revenue markets disclosed.

Source: SEC 10-K, filed 2026-04-15

Industry: In Vitro & In Vivo Diagnostic Substances Peers: SEELOS THERAPEUTICS, INC. Assertio Holdings Inc LeonaBio Inc Dare Bioscience Inc Johnson & Johnson Trevi Therapeutics Inc TFF Pharmaceuticals, Inc.